SEC Form 4 · accession 0001415889-18-000104
Niagen Bioscience, Inc. · NAGE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Frank L Jaksch Jr.
Officer — CEO · Director
Period of report
Jan 21, 2018
Accepted (ET)
Jan 23, 2018 · 4:18 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001386570
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Options (right to buy)F1 | $5.85 | Jan 21, 2018 | A | 50,000 | A | Jan 21, 2019 | Jan 21, 2028 | Common Stock | 50,000 | 50,000 | D |
Explanation of responses
- F1Options vest 25% on January 21, 2019 and thereafter 1/48th vest each month.